Detalhe da pesquisa
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307807
2.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol
; 33(10): 1021-1028, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772665
3.
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecol Oncol
; 164(3): 498-504, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35063276
4.
The systemic treatment of recurrent ovarian cancer revisited.
Ann Oncol
; 32(6): 710-725, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33675937
5.
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Ann Oncol
; 31(12): 1606-1622, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33004253
6.
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecol Oncol
; 159(3): 692-698, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077258
7.
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Gynecol Oncol
; 156(1): 45-53, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836184
8.
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 159(2): 442-448, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32981695
9.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol
; 30(5): 672-705, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046081
10.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Ann Oncol
; 30(7): 1080-1087, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046082
11.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Int J Gynecol Cancer
; 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31048403
12.
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Ann Oncol
; 29(6): 1366-1376, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750420
13.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(10): 833-848, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597580
14.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Ann Oncol
; 34(1): 33-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307055
15.
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Ann Oncol
; 29(2): 431-438, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186319
16.
Safety and dose modification for patients receiving niraparib.
Ann Oncol
; 29(8): 1784-1792, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767688
17.
Front-line therapy of advanced ovarian cancer: new approaches.
Ann Oncol
; 28(suppl_8): viii46-viii50, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29232475
18.
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 33(9): 860-877, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690222
19.
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
Ann Oncol
; 28(suppl_8): viii30-viii35, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29232472
20.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Ann Oncol
; 28(4): 711-717, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327917